美国大型门诊人群中人免疫缺陷病毒1型传播性耐药分子流行病学与遗传机制趋势
研究分析了2003至2016年加州一家门诊4253例未接受抗逆转录病毒治疗的HIV-1感染者反转录酶和蛋白酶序列,发现总体传播性耐药及非核苷类反转录酶抑制剂相关耐药显著增加,2012至2016年总体耐药率为15.7%至19.2%,但许多耐药株可能不影响当前首选一线方案活性。
要点
- 2003至2016年总体传播性耐药显著增加(OR 1.05/年,95%CI 1.03-1.08,P<.001)。
- 非核苷类反转录酶抑制剂相关传播性耐药亦显著增加(OR 1.11/年,95%CI 1.08-1.15,P<.001)。
- 2012至2016年总体传播性耐药率为15.7%至19.2%,NNRTI相关为10.0%至12.8%。
核心结论
- 尽管该大型队列中传播性耐药显著增加,许多传播性耐药株可能不影响当前首选一线抗逆转录病毒治疗方案活性。
- 与不常用方案相关的耐药突变比例高,加上传播性耐药株成簇,提示部分传播性耐药株在未治疗个体间传播。
研究设计与样本
- 研究纳入2003至2016年加州一家门诊人群中4253例未接受抗逆转录病毒治疗的个体,获取HIV-1反转录酶和蛋白酶序列。
- 采用系统发育分析研究传播性耐药株间的关联及传播性耐药相关耐药突变的选择压力。
主要发现
- 2003至2016年总体传播性耐药显著增加(OR 1.05/年,95%CI 1.03-1.08,P<.001)。
- 非核苷类反转录酶抑制剂相关传播性耐药显著增加(OR 1.11/年,95%CI 1.08-1.15,P<.001)。
- 2012至2016年对任一药物类别的传播性耐药率为15.7%至19.2%,NNRTI相关为10.0%至12.8%,NRTI相关为4.1%至8.1%,蛋白酶抑制剂相关为3.6%至5.2%。
- 胸苷类似物突变、M184V/I及替诺福韦相关耐药突变K65R和K70E/Q/G/N/T分别占NRTI相关传播性耐药的82.9%、7.3%和1.4%。
- 37%的传播性耐药株与其他共享相同耐药突变的传播性耐药株成簇。
临床怎么用
- 原文结论未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are few large studies of transmitted drug resistance (TDR) prevalence and the drug resistance mutations (DRMs) responsible for TDR in the United States. METHODS: Human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) and protease sequences were obtained from 4253 antiretroviral therapy (ART)-naive individuals in a California clinic population from 2003 to 2016. Phylogenetic analyses were performed to study linkages between TDR strains and selection pressure on TDR-associated DRMs. RESULTS: From 2003 to 2016, there was a significant increase in overall (odds ratio [OR], 1.05 per year [95% confidence interval {CI}, 1.03-1.08]; P < .001) and nonnucleoside RT inhibitor (NNRTI)-associated TDR (OR, 1.11 per year [95% CI, 1.08-1.15]; P < .001). Between 2012 and 2016, TDR rates to any drug class ranged from 15.7% to 19.2%, and class-specific rates ranged from 10.0% to 12.8% for NNRTIs, 4.1% to 8.1% for nucleoside RT inhibitors (NRTIs), and 3.6% to 5.2% for protease inhibitors. The thymidine analogue mutations, M184V/I and the tenofovir-associated DRMs K65R and K70E/Q/G/N/T accounted for 82.9%, 7.3%, and 1.4% of NRTI-associated TDR, respectively. Thirty-seven percent of TDR strains clustered with other TDR strains sharing the same DRMs. CONCLUSIONS: Although TDR has increased significantly in this large cohort, many TDR strains are unlikely to influence the activity of currently preferred first-line ART regimens. The high proportion of DRMs associated with infrequently used regimens combined with the clustering of TDR strains suggest that some TDR strains are being transmitted between ART-naive individuals.
引用
- Rhee SY, Clutter D, Fessel WJ, et al. Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted Human Immunodeficiency Virus Type 1 Drug Resistance in a Large US Clinic Population. Clin Infect Dis. 2019. PMID: 29846534. doi:10.1093/cid/ciy453
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。